HR19042 + Tarpeyo + Budenofalk

This is a **combination drug regimen** of three agents: HR19042, Tarpeyo (budesonide), and Budenofalk (budesonide). - **HR19042** is a small molecule anti-inflammatory drug developed by Jiangsu Hengrui Medicine for the treatment of autoimmune hepatitis and IgA nephropathy. Its exact mechanism of action has not been defined, but it is being studied in immune and urogenital diseases and is in phase 2/3 clinical trials for these conditions[1][4][7][10]. - **Tarpeyo** is an oral, delayed-release capsule formulation of budesonide, a corticosteroid, approved for reducing the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN). Budesonide works mainly as a locally active glucocorticoid with anti-inflammatory and immunosuppressive effects, modulating mucosal B-cell activity in the ileum to reduce Gd-IgA1, which is involved in IgAN pathogenesis[2][5][8]. - **Budenofalk** is another oral gastro-resistant capsule containing budesonide, primarily used for mild to moderate Crohn’s disease affecting the ileum and/or ascending colon, microscopic colitis, and autoimmune hepatitis. It also uses the anti-inflammatory properties of budesonide, with the effect localized to the gastrointestinal tract[3][6][9].

Other names

HR19042HR-19042HR 19042